Navigation Links
Non-Hormonal Therapies Aid Breast Cancer Patients
Date:12/9/2008

This applies to women with metastatic or recurrent inoperable disease, report says

TUESDAY, Dec. 9 (HealthDay News) -- Over the last 35 years, non-hormonal treatments have improved overall survival of patients with advanced breast cancer.

So say Greek researchers who conducted a review of 128 clinical trials that included more than 26,000 women with the disease.

The review showed that use of anthracycline regimens led to a 22 percent relative risk reduction in overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reduction over single-agent chemotherapy.

Most of the regimens appeared to be effective whether or not women had received a prior treatment.

"Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically indistinguishable in magnitude," the review authors wrote. "Given that subsequent lines of treatment can confer similar relative benefits as the first-line setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion."

The study was published Dec. 9 in the Journal of the National Cancer Institute.

This review is important because there has been no consensus regarding the best dosage, timing, sequence or combination of therapies for treatment of metastatic breast cancer, due to the fact that standard comparators haven't been available, Dr. Philippe Bedard and Dr. Martine Piccart-Gebhart, of the Jules Bordet Institute in Brussels, Belgium, wrote in an accompanying editorial.

The finding that many of the regimens have similar relative effectiveness in both untreated and previously treated patients means that other considerations, such as toxicity, will continue to help determine the choice of regimen for individual patients, the researchers said.

"Although this network meta-analysis is unlikely to alter routine clinical practice, it provides a solid evidence-based foundation to support the observation that the survival of women diagnosed with advanced breast cancer has improved because of more active systemic chemotherapy and targeted therapy," Bedard and Piccart-Gebhart wrote. "This should provide hope to patients, investigators, industrial sponsors, and regulatory agencies alike that well-designed clinical trials with novel systemic therapies can further alter the natural history of this devastating disease."

More information

Breastcancer.org has more about recurrent and metastatic breast cancer.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Bogus Stem Cell Therapies Sold on Internet
2. Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017
3. Non-white med students reject therapies associated with their culture
4. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
5. Stem cell therapies for heart disease -- 1 step closer
6. Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies
7. Study shows steroid therapies following transplant can be eliminated
8. Study Evaluates Laser Therapies for Hair Removal
9. New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!
10. New way to control protein activity could lead to cancer therapies
11. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: